SETD2 and urothelial carcinoma: A total of 6726 samples were analyzed and the results showed that renal cell carcinoma had the highest SETD2 mutational frequency (13/93; 13.98%) followed by prostate cancer (5/52; 9.62%), urothelial carcinoma (7/75; 9.33%), glioma (17/215; 7.91%), hepatic carcinoma (15/195; 7.69%), colorectal cancer (74/1156; 6.4%), melanoma (8/136; 5.88%), and NSCLC (203/3630; 5.84%).